Latest Data: How ctDNA can transform interventional trial design for GI cancers

Detection of molecular residual disease (MRD) by circulating tumor DNA (ctDNA) has become an important biomarker in optimizing clinical trials and for patient management across multiple solid tumors. The Signatera MRD assay has been shown to identify high-risk patients who are likely to relapse without additional/novel treatment, underscoring a need for more interventional trials in these populations.

Join our discussion on the latest data from ASCO GI including 2024 publications validating the prognostic and predictive capabilities of ctDNA in colorectal, gastroesophageal, and pancreatic cancers.

Data to be discussed include, but is not limited to:
  • Updated analyses from the prospective CIRCULATE-JAPAN study across almost 3,000 patients with colorectal cancer demonstrated that ctDNA detection at a single time point 2-10 weeks post-surgery was predictive of 24-month DFS (Yukami et al., ASCO GI 2024)
    • Over 50% of stage II-III patients who were ctDNA+ post-surgery relapsed within 24 months despite receiving adjuvant chemotherapy, highlighting a need for additional/novel treatment in this population
  • Results from the MD Anderson INTERCEPT program, showing that in a prospective cohort of patients with resectable Stage II-IV CRC, ctDNA surveillance identified MRD-only recurrence ahead of radiographic progression, providing an opportunity for early treatment in interventional trials (Dasari et al., ASCO 2023, Pellatt, et al., ASCO GI 2024)
    • Additionally, the prognostic importance of ctDNA at the post-operative time point exceeded the risk prediction of stage alone (Maddalena et al., ASCO GI 2024)
  • Results from a phase 1 trial for an investigational therapy using ctDNA positivity and/or elevated serum tumor antigen levels to enroll and assess treatment response for patients with KRAS-mutated pancreatic or colorectal cancer (Pant et al., Nat Med. 2024)
  • Results from the PANDA phase II trial for preoperative atezolizumab plus chemotherapy in patients with resectable, non-metastatic GEC cancers showing the strong correlation between ctDNA and pathologic response pre-surgery and with associated recurrence risk, highlighting the potential clinical utility of Signatera. (Verschoor et al, Nat Med. 2024)
  • This will be followed by a panel discussion on the state of the field, future directions, and implications for clinical trial design.
watch now
Watch the webinar on demand
Adham Jurdi

Adham Jurdi

Oncology Medical Director, Natera

Adham Jurdi, MD, is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr. Jurdi practiced at Austin Cancer Center, SUNY Upstate Medical University and the Syracuse VAMC. Throughout his clinical career, he was involved in GI oncology and precision medicine research.

John Simmons

John Simmons

Global VP Biopharma, Natera

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.